251,932 MiMedx Group, Inc $MDXG Shares Purchased by State of Wyoming

State of Wyoming boosted its position in MiMedx Group, Inc (NASDAQ:MDXG) by 347.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 324,492 shares of the company’s stock after purchasing an additional 251,932 shares during the period. State of Wyoming owned about 0.22% of MiMedx Group worth $1,512,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Isthmus Partners LLC increased its position in shares of MiMedx Group by 3.5% in the third quarter. Isthmus Partners LLC now owns 549,411 shares of the company’s stock valued at $2,560,000 after buying an additional 18,702 shares in the last quarter. Quadrant Capital Group LLC boosted its position in shares of MiMedx Group by 59.8% in the 3rd quarter. Quadrant Capital Group LLC now owns 141,091 shares of the company’s stock worth $662,000 after buying an additional 52,824 shares in the last quarter. Abel Hall LLC boosted its position in shares of MiMedx Group by 18.0% in the 3rd quarter. Abel Hall LLC now owns 80,573 shares of the company’s stock worth $375,000 after buying an additional 12,284 shares in the last quarter. NorthCrest Asset Manangement LLC purchased a new stake in shares of MiMedx Group in the 3rd quarter worth about $63,000. Finally, GAMMA Investing LLC grew its stake in MiMedx Group by 2,422.5% in the 3rd quarter. GAMMA Investing LLC now owns 7,719 shares of the company’s stock valued at $36,000 after acquiring an additional 7,413 shares during the last quarter. 79.15% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have weighed in on MDXG. Wall Street Zen upgraded shares of MiMedx Group from a “sell” rating to a “hold” rating in a report on Saturday, August 29th. Craig Hallum lifted their target price on shares of MiMedx Group from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Thursday, August 27th. Seaport Research Partners downgraded shares of MiMedx Group to a “neutral” rating in a report on Monday, August 17th. Mizuho set a $7.00 price target on shares of MiMedx Group in a research report on Thursday. Finally, Weiss Ratings lowered shares of MiMedx Group from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday. Six analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.14.

MiMedx Group Stock Down 2.3%

NASDAQ MDXG opened at $3.88 on Friday. MiMedx Group, Inc has a fifty-two week low of $3.03 and a fifty-two week high of $7.97. The stock has a market cap of $565.55 million, a price-to-earnings ratio of -29.85 and a beta of 1.18. The business has a fifty day moving average of $4.49 and a 200-day moving average of $4.29.

MiMedx Group (NASDAQ:MDXG) last issued its quarterly earnings data on Wednesday, October 28th. The company reported ($0.01) earnings per share (EPS) for the quarter. The company had revenue of $62.28 million during the quarter, compared to analysts’ expectations of $68.56 million. MiMedx Group had a negative net margin of 6.32% and a positive return on equity of 2.39%. As a group, analysts anticipate that MiMedx Group, Inc will post -0.10 EPS for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc (NASDAQ: MDXG) is a biotechnology company focused on developing and commercializing human placental tissue allografts for wound care and other medical applications. The company’s products are derived from donated placental tissue and are processed using its proprietary PURION technology platform.

MiMedx’s portfolio includes tissue-based products such as EPIFIX and EPICORD, which are used primarily by healthcare professionals in the management of chronic and acute wounds, including diabetic foot ulcers and other hard-to-heal wounds.